Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jun 21:6:27251.
doi: 10.1038/srep27251.

Factors influencing immunologic response to hepatitis B vaccine in adults

Shigui Yang  1 , Guo Tian  1 , Yuanxia Cui  1 , Cheng Ding  1 , Min Deng  1 , Chengbo Yu  1 , Kaijin Xu  1 , Jingjing Ren  1 , Jun Yao  2 , Yiping Li  3 , Qing Cao  1 , Ping Chen  1 , Tiansheng Xie  1 , Chencheng Wang  1 , Bing Wang  1 , Chen Mao  4   5 , Bing Ruan  1 , Tian'an Jiang  6 , Lanjuan Li  1
Affiliations
Meta-Analysis

Factors influencing immunologic response to hepatitis B vaccine in adults

Shigui Yang et al. Sci Rep. .

Abstract

Hepatitis B was still a worldwide health problem. This study aimed to conducted a systematic review and meta-analysis to assess a more precise estimation of factors that influence the response to hepatitis B vaccine in adults. Our included studies examined seroprotection rates close to the end of vaccination schedules in healthy adult populations. This meta-analysis including 21053 adults in 37 articles showed that a significantly decreased response to hepatitis B vaccine appeared in adults (age ≥ 40) (RR:1.86, 95% CI:1.55-2.23), male adults (RR:1.40, 95% CI:1.22-1.61), BMI ≥ 25 adults (RR:1.56, 95% CI:1.12-2.17), smoker (RR:1.53, 95% CI:1.21-1.93), and adults with concomitant disease (RR:1.39, 95% CI:1.04-1.86). Meanwhile, we further found a decreased response to hepatitis B vaccine appeared in adults (age ≥ 30) (RR:1.77, 95% CI:1.48-2.10), and adults (age ≥ 60) (RR:1.30, 95% CI:1.01-1.68). However, there were no difference in response to hepatitis B vaccine both in alcoholic (RR:0.90, 95% CI:0.64-1.26) and 0-1-12 vs. 0-1-6 vaccination schedule (RR:1.39, 95% CI:0.41-4.67). Pooling of these studies recommended the sooner the better for adult hepatitis B vaccine strategy. More vaccine doses, supplemental/additional strengthening immunity should be emphasized on the susceptible population of increasing aged, male, BMI ≥ 25, smoking and concomitant disease. The conventional 0-1-6 vaccination schedule could be still worth to be recommended.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow diagram of the study selection process.
Figure 2
Figure 2
(a) The relative risks of response to HBV vaccine between adults age ≥40 and adults age <40. (b) The relative risks of response to HBV vaccine between adults age ≥40 and adults age <40. Comparing with adults age <40, the RRs show decreased response to HBV vaccine among adults age ≥40 in cohort and overall studies.
Figure 3
Figure 3
(a) The relative risks of response to HBV vaccine between adults age ≥30 and adults age <30. (b) The relative risks of response to HBV vaccine between adults age ≥30 and adults age <30 grouped by study design. Comparing with adults age <30, the RRs indicate reduced response to HBV vaccine among adults age ≥30 both in cohort and RCT studies.
Figure 4
Figure 4
(a) The relative risks of response to HBV vaccine between adults age ≥60 and adults age <60. (b) The relative risks of response to HBV vaccine between male adults and female adults. (c) The relative risks of response to HBV vaccine between male adults and female adults grouped by study design. Comparing with female adults, The RRs suggest declined response to HBV vaccine among male adults both in cohort and RCT studies. (d) The relative risks of response to HBV vaccine between BMI ≥25 adults and BMI <25 adults.
Figure 5
Figure 5
(a) The relative risks of response to HBV vaccine between smoker and nonsmoker. (b) The relative risks of response to HBV vaccine between alcoholic and nonalcoholic. (c) The relative risk of response to HBV vaccine between adults with concomitant disease and healthy adults. (d) The relative risk of response to HBV vaccine between 0-1-12 and 0-1-6 vaccination schedule.
See this image and copyright information in PMC

References

    1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of viral hepatitis 11, 97–107 (2004). - PubMed
    1. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. European Centre for Disease Prevention and Control. 56 p. doi: 10.2900/30933 (Stockholm, 2010). - DOI
    1. Hahne S. J. et al. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC infectious diseases 13, 181, doi: 10.1186/1471-2334-13-181 (2013). - DOI - PMC - PubMed
    1. Keck J. W. et al. Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons. Clinical and vaccine immunology: CVI 21, 1339–1342, doi: 10.1128/CVI.00263-14 (2014). - DOI - PMC - PubMed
    1. Bruce M. G. et al. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. The Journal of infectious diseases, doi: 10.1093/infdis/jiv748 (2016). - DOI - PubMed

Publication types

Substances